Results 11 to 20 of about 4,490 (182)

MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements

Cancer Medicine, 2023
Background Entrectinib is an effective drug for treating solid tumors with NTRK gene rearrangement and non‐small cell lung cancer (NSCLC) with ROS1 gene rearrangement.
Yohei Takumi, Sachiko Arai, Chiaki Suzuki, Koji Fukuda, Akihiro Nishiyama, Shinji Takeuchi, Hiroki Sato, Kunio Matsumoto, Kenji Sugio, Seiji Yano   +9 more
doaj   +2 more sources

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report

JTO Clinical and Research Reports, 2023
Resistance to ROS1 tyrosine kinase inhibitors is inevitable, but it has been unclear whether crizotinib might be effective after the development of entrectinib resistance. We here present a case of ROS1-rearranged NSCLC that responded to crizotinib after
Toshiaki Takakura, MD, Hiroaki Kanemura, MD, MPH, Kazuko Sakai, PhD, Kazuto Nishio, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Hidetoshi Hayashi, MD, PhD   +5 more
doaj   +2 more sources

Entrectinib‐induced syndrome of inappropriate antidiuretic hormone secretion in a patient with ROS1‐rearranged non‐small cell lung cancer

Respirology Case Reports, 2023
A 75‐year‐old woman was referred to our hospital because of a productive cough and an abnormal shadow on chest radiography. She was diagnosed as having metastatic lung adenocarcinoma harbouring ROS proto‐oncogene 1 (ROS1).
Chiaki Kato, Muneyuki Sekiya, Ryo Sekiguchi, Akira Yamasaki, Takahiro Yoshizawa, Kazutoshi Isobe, Naobumi Tochigi, Kazutoshi Shibuya, Kazuma Kishi   +8 more
doaj   +2 more sources

Targeting PYK2, entrectinib allays anterior subcapsular cataracts in mice by regulating TGFβ2 signaling pathway

Molecular Medicine
Background Fibrosis cataract occurs in patients receiving cataract extraction. Still, no medication that can cure the disease exists in clinical. This study aims to investigate the effects and mechanisms of Entrectinib on fibrotic cataract in vitro and ...
Xuefei Ding, Xiaohe Li, Rui Fang, Peilin Yue, Yuxuan Jia, Enjie Li, Yayue Hu, Honggang Zhou, Xudong Song   +8 more
doaj   +2 more sources

Entrectinib use in a platinum-refractory mucinous ovarian cancer harboring a NTRK3 gene fusion

Gynecologic Oncology Reports, 2023
Ovarian cancer is difficult to treat, and the mucinous epithelial subtype has a particularly poor response to traditional chemotherapy regimens. Entrectinib is a tumor-agnostic tyrosine kinase inhibitor with limited data regarding its use in ovarian ...
Olivia G. Beck, Melissa M. Hardesty
doaj   +2 more sources

Entrectinib-Induced Myocarditis and Acute Heart Failure Responding to Steroid Treatment: A Case Report [PDF]

JTO Clinical and Research Reports
A 72-year-old man presented to his general practitioner with worsening dyspnea and was diagnosed with having recurrent ROS1-positive stage IIIB NSCLC 8 years after initial diagnosis and radical treatment for early stage disease.
Mehraab N. Majeed, MBBCh, Subramanian Venkatesan, PhD, Dionysis Papadatos-Pastos, PhD, Tanya Ahmad, MD, Martin Forster, PhD, Polyvios Demetriades, MRCP, Daniel Johnathan Hughes, MRCP, Sarah Benafif, PhD, Siow Ming Lee, FRCP   +8 more
doaj   +2 more sources

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma

Drug Design, Development and Therapy, 2018
Holly L Pacenta, Margaret E Macy Department of Pediatrics, University of Colorado Anschutz Medical Campus and Children’s Hospital Colorado, Aurora, CO, USA Abstract: RTK plays important roles in many cellular signaling processes involved in ...
Pacenta HL, Macy ME
doaj   +1 more source

Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer. [PDF]

, 2022
Larotrectinib and entrectinib are tumor-agnostic tropomyosin receptor kinase (TRK) inhibitors that are indicated for the treatment of advanced or metastatic solid tumor cancers with neurotrophic tyrosine receptor kinase (NTRK) gene fusions.
Carlson, Josh J, Sullivan, Sean D, Italiano, Antoine, Lassen, Ulrik, Brose, Marcia S, Federman, Noah, Kummar, Shivaani   +6 more
core   +3 more sources

Refractory response to entrectinib for ROS‐1 rearranged NSCLC with concurrent de novo TP53 mutation showing good response to CNS lesion, but poor duration of response: A case report

Thoracic Cancer, 2023
Entrectinib, a ROS‐1 inhibitor, has been shown to be effective for patients with ROS‐1 fused NSCLC, and has been established as the standard of care for this population.
Kentaro Ito, Miho Nishio, Kentaro Fujiwara, Yoichi Nishii, Kengo Ushiro, Hiroki Yasui, Osamu Hataji   +6 more
doaj   +1 more source

A case of hepatic dysfunction from crizotinib followed by treatment with entrectinib

Current Problems in Cancer: Case Reports, 2023
Background: Information regarding the safety of entrectinib for previously treated patients and patients with hepatic dysfunction is limited. This is the first case report of treatment modification attributable to hepatic dysfunction caused by crizotinib.
Takahito Mizuno, Satoshi Hagimoto, Takumi Umemura, Mariko Higashikawa, Takamasa Sakai, Kouichi Tanabe, Fumiko Ohtsu, Tetsuya Yamada, Tomoki Kimura   +8 more
doaj   +1 more source